BioPharmaTrend
Latest News
All Topics
  • Artificial Intelligence
  • NeuroTech
  • Premium Content
  • Knowledge Center
Interviews
Companies
  • Company Directory
  • Sponsored Case Studies
  • Create Company Profile
More
  • About Us
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
  • Write for Us
Subscribe
Login/Join

  Latest News

Insilico Medicine Initiates Phase I Clinical Trial for Novel QPCTL Inhibitor

by Roman Kasianov   •   May 17, 2024  

Disclaimer: All opinions expressed by Contributors are their own and do not represent those of their employers, or BiopharmaTrend.com.
Contributors are fully responsible for assuring they own any required copyright for any content they submit to BiopharmaTrend.com. This website and its owners shall not be liable for neither information and content submitted for publication by Contributors, nor its accuracy.

# Clinical Trials   
Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email

Insilico Medicine, a biotechnology company specializing in generative artificial intelligence, has begun dosing patients in the first clinical trial for ISM8207, a small molecule inhibitor targeting QPCTL. This drug candidate, co-developed with Fosun Pharma, is being tested for its efficacy in treating advanced malignant tumors.

#advertisement
How BenchSci’s ASCEND Builds a Map for Biomedical Reasoning

The Phase I clinical trial, taking place in China, is an open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ISM8207 in patients with lymphoma and other advanced solid tumors. The trial, registered under CTR20240727, aims to establish the recommended dose for future studies while assessing the drug's safety and effectiveness.

ISM8207 is designed to inhibit Glutaminyl-Peptide Cyclotransferase-Like Protein (QPCTL), a protein involved in the post-translational modification of the "don't eat me" signal protein CD47. This modification allows cancer cells to evade the immune system by interacting with signal regulatory protein alpha (SIRPα) on macrophages. QPCTL also modifies chemokines that contribute to an immune-suppressive tumor microenvironment. By inhibiting QPCTL, ISM8207 may disrupt these modifications, thereby enhancing the immune system's ability to recognize and attack cancer cells.

See also: From Gene Editing to Pathway Design: How AI is Transforming Synthetic Biology

Developed using Insilico's generative AI platform, Pharma.AI, ISM8207 has shown promising preclinical results. These studies demonstrated significant synergistic anti-tumor effects when used in combination with other therapies against multiple solid tumors and hematologic malignancies. The drug also displayed favorable in vitro ADME (absorption, distribution, metabolism, and excretion) and in vivo pharmacokinetic (PK) profiles.

Dr. Feng Ren, co-CEO and Chief Scientific Officer of Insilico Medicine, highlighted the significance of ISM8207's progression to clinical trials.

"Compared to current strategies that interfere with the CD47-SIRPα signaling pathway, ISM8207 potentially provides a better margin of safety. It not only can enhance immune recognition and attack against cancer cells, but also potentially enhance the anti-cancer efficacy of various standard-of-care therapies."

The collaboration between Insilico Medicine and Fosun Pharma began in January 2022, focusing on AI-driven drug discovery. ISM8207, which received Investigational New Drug (IND) approval from the Chinese Center for Drug Evaluation (CDE) in July 2023, is one of the most advanced projects under this partnership.

Insilico Medicine has a robust pipeline powered by its Pharma.AI platform, with 18 preclinical candidates nominated since 2021. Seven of these molecules have received IND approvals. In March 2024, the company published a paper in Nature Biotechnology detailing the experimental data and evaluations of its lead drug, a TRAF2- and NCK-interacting kinase (TNIK) inhibitor for idiopathic pulmonary fibrosis, which is currently in Phase II trials.

Fosun Pharma Insilico Medicine

Topics: Clinical Trials   

Share:   Share in LinkedIn  Share in Bluesky  Share in Reddit  Share in Hacker News  Share in X  Share in Facebook  Send by email
#advertisement
ThermoFisher Scientific: Integrated genetic technologies for cell therapy development
#advertisement
Webinar: AI in Clinical Trials

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
gnews  Google News
rss  RSS Feed

About


  • What we do
  • Citations and Press Coverage
  • Terms of Use
  • Privacy Policy
  • Disclaimer

We Offer


  • Premium Content
  • BioTech Scout
  • Interviews
  • Partner Events
  • Case Studies

Opportunities


  • Membership
  • Advertise
  • Submit Company
  • Write for Us
  • Contact Us

© BPT Analytics LTD 2025
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.